MetaVia (NASDAQ:MTVA) Posts Quarterly Earnings Results

MetaVia (NASDAQ:MTVA) announced its quarterly earnings results on Wednesday. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03), Zacks reports.

MetaVia Stock Down 6.7%

NASDAQ:MTVA traded down $0.08 during trading hours on Friday, reaching $1.11. 36,137 shares of the company’s stock were exchanged, compared to its average volume of 217,317. The company has a market capitalization of $5.73 million, a P/E ratio of -0.13 and a beta of 0.59. MetaVia has a 12 month low of $0.97 and a 12 month high of $19.03. The business’s 50-day simple moving average is $1.40 and its two-hundred day simple moving average is $4.58.

Analyst Ratings Changes

MTVA has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of MetaVia from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research note on Friday, April 24th. Finally, HC Wainwright lowered their price objective on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, MetaVia currently has a consensus rating of “Hold” and a consensus target price of $26.50.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent filing with the Securities and Exchange Commission (SEC). 1.37% of the stock is owned by institutional investors and hedge funds.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.